SG10201608136SA - Anti-hla-b*27 antibodies and uses thereof - Google Patents

Anti-hla-b*27 antibodies and uses thereof

Info

Publication number
SG10201608136SA
SG10201608136SA SG10201608136SA SG10201608136SA SG10201608136SA SG 10201608136S A SG10201608136S A SG 10201608136SA SG 10201608136S A SG10201608136S A SG 10201608136SA SG 10201608136S A SG10201608136S A SG 10201608136SA SG 10201608136S A SG10201608136S A SG 10201608136SA
Authority
SG
Singapore
Prior art keywords
hla
antibodies
Prior art date
Application number
SG10201608136SA
Other languages
English (en)
Inventor
Andrew J Murphy
Ana Kostic
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201608136SA publication Critical patent/SG10201608136SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG10201608136SA 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof SG10201608136SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618969P 2012-04-02 2012-04-02
US201361778703P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201608136SA true SG10201608136SA (en) 2016-11-29

Family

ID=48093122

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201405759UA SG11201405759UA (en) 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof
SG10201608136SA SG10201608136SA (en) 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201405759UA SG11201405759UA (en) 2012-04-02 2013-04-02 Anti-hla-b*27 antibodies and uses thereof

Country Status (22)

Country Link
US (1) US9790273B2 (enExample)
EP (1) EP2834272B1 (enExample)
JP (1) JP6320993B2 (enExample)
KR (1) KR20150003256A (enExample)
CN (1) CN104169302A (enExample)
AR (1) AR090585A1 (enExample)
AU (1) AU2013243644C1 (enExample)
BR (1) BR112014024622A2 (enExample)
CA (1) CA2868907C (enExample)
CL (1) CL2014002631A1 (enExample)
CO (1) CO7121320A2 (enExample)
EA (1) EA201491827A1 (enExample)
HK (1) HK1207092A1 (enExample)
IL (2) IL234707A0 (enExample)
MX (1) MX365690B (enExample)
MY (1) MY171180A (enExample)
NZ (1) NZ700650A (enExample)
PH (1) PH12014502184A1 (enExample)
SG (2) SG11201405759UA (enExample)
TW (1) TWI619729B (enExample)
UY (1) UY34721A (enExample)
WO (1) WO2013152001A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
EP2728002B1 (en) 2011-06-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
CN104838000B (zh) 2012-07-27 2022-12-20 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
ES2807424T3 (es) * 2015-02-04 2021-02-23 Univ Zuerich Uso de homodímeros de hla-b27 para el tratamiento del cáncer
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
CN114230670B (zh) 2015-02-27 2025-06-03 美商生物细胞基因治疗有限公司 靶向血液恶性肿瘤之嵌合抗原受体（car）、其组合物及使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP6961497B2 (ja) 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
EP3341738A4 (en) 2015-08-24 2019-02-27 University of Cincinnati METHOD AND COMPOSITIONS FOR DETECTING FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES
EP3347045A4 (en) * 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
AU2016372934B2 (en) * 2015-12-18 2023-10-05 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
BR112018068135A2 (pt) 2016-03-08 2019-01-08 Univ Basel conformador aberto de hla-b57
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US11279747B2 (en) 2016-08-10 2022-03-22 Universitat Zurich MHC class Ia fusion dimers for treatment of cancer
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US20200114022A1 (en) * 2017-03-31 2020-04-16 Alma Bio Therapeutics Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
CA3070578A1 (en) 2017-06-21 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
CN108486226B (zh) * 2018-04-01 2022-04-12 广东辉锦创兴生物医学科技有限公司 Hla-b27等位基因的检测试剂盒及其应用
CN118754986A (zh) 2018-08-10 2024-10-11 中外制药株式会社 抗cd137抗原结合分子及其应用
CA3133419A1 (en) * 2019-03-21 2020-09-24 Gamida Cell Ltd. Expansion and use of expanded nk cell fractions suitable for transplantation in combination therapy
WO2020230834A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
CN111175490A (zh) * 2020-01-19 2020-05-19 泛肽生物科技(浙江)有限公司 一种定性检测hla-b27的试剂盒及其检测方法
US12370257B2 (en) 2021-04-07 2025-07-29 Regeneron Pharmaceuticals, Inc. Materials and methods of treating MHC-I-opathy risk haplotypes
JP2024536491A (ja) * 2021-10-14 2024-10-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 小胞体アミノペプチダーゼ１（ｅｒａｐ１）阻害剤によるぶどう膜炎の治療
US20250302956A1 (en) * 2022-05-13 2025-10-02 Memorial Sloan-Kettering Cancer Center Compositions and methods for modulating tcr specificity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0213824B1 (en) * 1985-08-16 1995-05-24 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant-B27
US5369010A (en) * 1985-08-16 1994-11-29 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant -B27
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
WO2012047294A2 (en) * 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途

Also Published As

Publication number Publication date
UY34721A (es) 2013-10-31
US9790273B2 (en) 2017-10-17
CL2014002631A1 (es) 2015-01-16
CA2868907C (en) 2022-01-04
IL256716A (en) 2018-03-29
HK1207092A1 (en) 2016-01-22
MX2014011898A (es) 2014-11-12
WO2013152001A3 (en) 2013-12-27
US20130259876A1 (en) 2013-10-03
JP2015514110A (ja) 2015-05-18
EA201491827A1 (ru) 2015-03-31
NZ700650A (en) 2017-02-24
WO2013152001A2 (en) 2013-10-10
EP2834272A2 (en) 2015-02-11
CO7121320A2 (es) 2014-11-20
IL234707A0 (en) 2014-11-30
CA2868907A1 (en) 2013-10-10
KR20150003256A (ko) 2015-01-08
MY171180A (en) 2019-09-30
SG11201405759UA (en) 2014-11-27
AU2013243644B2 (en) 2018-02-08
AU2013243644A1 (en) 2014-10-23
MX365690B (es) 2019-06-11
EP2834272B1 (en) 2020-06-24
JP6320993B2 (ja) 2018-05-09
CN104169302A (zh) 2014-11-26
AR090585A1 (es) 2014-11-26
TW201343675A (zh) 2013-11-01
BR112014024622A2 (pt) 2017-08-08
TWI619729B (zh) 2018-04-01
PH12014502184A1 (en) 2014-12-10
AU2013243644C1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
IL256716A (en) Antibodies against hla–b*27 and their uses
IL235392B (en) Anti-egfr antibodies and their uses
IL254416A0 (en) Anti-asic1 antibodies and their uses
ZA201500457B (en) Anti-kit antibodies and uses thereof
EP2861622A4 (en) Anti-idiotypic anti-CD22 antibodies and uses thereof
IL233757A0 (en) Anti '1m e-gi antibodies and methods of using them
IL237287A0 (en) Antibody compositions and their uses
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
ZA201408213B (en) Anti-transglutaminase 2 antibodies
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
IL237400A0 (en) Rhizobacteria and its uses
GB201208372D0 (en) Antibodies and uses thereof